Navigation Links
China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York
Date:5/15/2009

TAIAN CITY, Shandong, China, May 15 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) (''China Biologic'' or the ''Company''), one of the leading plasma-based pharmaceutical companies in the People's Republic of China (''PRC''), today announced that the Company's management will present at the upcoming China Rising Conference hosted by CCG Investor Relations in New York, NY on May 18, 2009 and the 3rd Annual China Dragon Call Conference hosted by Oppenheimer & Co. Inc. on May 19 to 21, 2009.

The date, time and location of China Biologic' presentation at the China Rising Conference is as follows:

        Date:           Monday, May 18, 2009
        Time:           10:30 a.m. to 11:00 a.m. Eastern Time
        Presenter:      Tristan Kuo, Chief Financial Officer of China
                         Biologic
        Venue:          The Yale Club
                        50 Vanderbilt Avenue
                        New York, NY 10017
        Webcast:       http://www.chinarisingconference.com/webcast.html

A replay of the webcast will be available for up to one year following the presentation using the same link.

The China Rising Investment Conference hosted by CCG Investor Relations will provide over 250 fund managers and investors access to senior management of a wide range of Chinese growth companies in sectors including consumer staples, agriculture, pharmaceuticals, infrastructure, information technology, advanced materials, capital goods, and alternative energy. The conference will include over 30 US-listed Chinese companies and a number of private companies.

Interested parties and investors may find more information for the conference by visiting the website at http://www.chinarisingconference.com .

The date, time and location of China Biologic's presentation at the Oppenheimer 3rd Annual China Dragon Call Conference are as follows:

        Date:           Tuesday, May 19, 2009
        Time:           10:15 p.m. to 10:45 p.m. Eastern Time
        Presenter:      Tristan Kuo, Chief Financial Officer of China Biologic
        Venue:          300 Madison Avenue
                        New York City

The China Dragon Call Conference hosted by Oppenheimer & Co. Inc. will provide intimate access to senior management of leading Chinese companies. These discussions will give investors an ability to analyze secular trends, to identify emerging opportunities and to gather insight into China's investment outlook.

All conferences are for institutional clients of Oppenheimer & Co. Inc. and are by invitation only. For more information, please contact Oppenheimer & Co. Inc. institutional sales representative.

About China Biologic Products, Inc.

China Biologic Products, Inc. (the ''Company''), through its indirect majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., and equity investments in Xi'an Huitian Blood Products Co., Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd. is currently the largest non-state-owned plasma-based biopharmaceutical company approved by the Chinese government. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's blood products are irreplaceable in the application of medical emergencies, and prevention and treatment for various diseases. It sells its plasma-based biopharmaceutical products to hospitals and other healthcare facilities in China.

Safe Harbor Statement

This release may contain certain ''forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are ''forward-looking statements," including statements regarding: the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," ''expects'' or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    For more information, please contact:

    Company Contact:
     Mr. Y. Tristan Kuo
     Chief Financial Officer
     China Biologic Products, Inc.
     Tel:   +86-538-6202206
     Email: IR@chinabiologic.com
     Web:  http://www.chinabiologic.com

    Investor Relations Contact:
     Mr. Crocker Coulson, President
     CCG Investor Relations
     Tel:   +1-646-213-1915 (NY office) or
     Mr. Gary Chin
     Tel:   +1-646-213-1909
     Email: crocker.coulson@ccgir.com
     Web: http://www.ccgirasia.com

'/>"/>
SOURCE China Biologic Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results
2. China-Biotics, Inc. to Present at CCG Investor Relations China Rising Conference
3. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
4. China Medical Technologies Receives SFDA Approval for Its Bladder Cancer FISH Probe
5. China Sky One Medical, Inc. Obtains SFDA Approvals for Geranium Ointment and Musk Liniment for Pain Relief
6. China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results
7. China Breaks Ground on Largest Comprehensive Stem Cell Storage and Processing Facility
8. China-Biotics, Inc. Supplies Probiotics as Additive for Poultry Feed
9. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
10. China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
11. China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
Breaking Biology News(10 mins):